Globus Medical (GMED) 10-Q 5 May 15 2015 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2015	Apr. 20, 2015
Document Information
Entity Registrant Name	GLOBUS MEDICAL INC
Entity Central Index Key	1237831
Current Fiscal Year End Date	-19
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	31-Mar-15
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	Q1
Amendment Flag	FALSE
Entity Common Stock, Shares Outstanding		94,908,608

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
ASSETS
Cash and cash equivalents	$75,006	$82,265
Restricted cash	23,370	23,370
Short-term marketable securities	138,274	146,439
Accounts receivable, net of allowances of $1,567 and $1,647, respectively	73,174	75,430
Inventories	98,947	90,945
Prepaid expenses and other current assets	5,054	5,742
Income taxes receivable	529	5,772
Deferred income taxes	41,341	40,062
Total current assets	455,695	470,025
Property and equipment, net of accumulated depreciation of $123,430 and $118,544, respectively	87,916	69,475
Long-term marketable securities	71,513	75,347
Intangible assets, net	34,342	34,529
Goodwill	93,573	53,196
Other assets	1,090	975
Total assets	744,129	703,547
LIABILITIES AND EQUITY
Accounts payable	19,384	15,904
Accounts payable to related-party	0	5,359
Accrued expenses	57,817	61,499
Income taxes payable	9,557	569
Business acquisition liabilities, current	6,553	6,081
Total current liabilities	93,311	89,412
Business acquisition liabilities, net of current portion	25,802	20,195
Deferred income taxes	7,520	5,166
Other liabilities	3,332	3,320
Total liabilities	129,965	118,093
Commitments and contingencies (Note 12)
Equity:
Additional paid-in capital	179,482	175,242
Accumulated other comprehensive loss	-1,835	-1,657
Retained earnings	436,422	411,774
Total equity	614,164	585,454
Total liabilities and equity	744,129	703,547
Class A Common
Equity:
Common stock	71	71
Class B Common
Equity:
Common stock	$24	$24

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parentheticals) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, except Share data, unless otherwise specified
Current Assets:
Allowance for doubtful accounts	$1,567	$1,647
Property, Plant and Equipment, Net
Accumulated depreciation	$123,430	$118,544
Equity:
Common stock, shares authorized	785,000,000
Common stock, shares issued	94,899,983	94,705,743
Common stock, shares outstanding	94,899,983	94,705,743
Class A Common
Equity:
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	71,022,427	70,828,187
Common stock, shares outstanding	71,022,427	70,828,187
Class B Common
Equity:
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	275,000,000	275,000,000
Common stock, shares issued	23,877,556	23,877,556
Common stock, shares outstanding	23,877,556	23,877,556

Consolidated_Statements_of_Inc

Consolidated Statements of Income (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Income Statement [Abstract]
Sales	$131,604	$114,210
Cost of goods sold	32,107	25,312
Gross profit	99,497	88,898
Operating expenses:
Research and development	8,656	7,443
Selling, general and administrative	52,289	46,678
Provision for litigation	32	2,535
Total operating expenses	60,977	56,656
Operating Income	38,520	32,242
Interest income, net	278	201
Foreign currency transaction loss	-677	-30
Other income	52	74
Total other income/(expense), net	-347	245
Income before income taxes	38,173	32,487
Income tax provision	13,525	11,348
Net Income	$24,648	$21,139
Earnings per share:
Basic	$0.26	$0.23
Diluted	$0.26	$0.22
Weighted average shares outstanding:
Basic	94,788	93,715
Dilutive stock options	1,117	1,457
Diluted	95,905	95,172
Anti-dilutive stock equivalents excluded from weighted average calculation	2,721	1,235

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Income (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Statement of Comprehensive Income [Abstract]
Net income	$24,648	$21,139
Other comprehensive income/(loss):
Unrealized gain on marketable securities, net of tax	65	1
Foreign currency translation loss	-243	-3
Total other comprehensive loss	-178	-2
Comprehensive Income	$24,470	$21,137

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Cash flows from operating activities:
Net income	$24,648	$21,139
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	5,674	5,297
Amortization of premium on marketable securities	640	801
Provision for excess and obsolete inventories	2,529	1,813
Stock-based compensation	2,131	1,927
Allowance for doubtful accounts	47	89
Change in deferred income taxes	-2,217	-2,415
(Increase)/decrease in:
Accounts receivable	1,888	-812
Inventories	-7,361	-3,993
Prepaid expenses and other assets	896	-562
Increase/(decrease) in:
Accounts payable	835	-1,096
Accounts payable to related-party	-5,359	1,184
Accrued expenses and other liabilities	-3,904	-2,015
Income taxes payable/receivable	14,223	7,875
Net cash provided by operating activities	34,670	29,232
Cash flows from investing activities:
Purchases of marketable securities	-72,874	-75,343
Maturities of marketable securities	64,574	46,250
Sales of marketable securities	19,764	14,280
Purchases of property and equipment	-7,228	-6,164
Acquisition of businesses, net of cash acquired	-48,015	0
Net cash used in investing activities	-43,779	-20,977
Cash flows from financing activities:
Payment of business acquisition liabilities	-300	-200
Proceeds from issuance of common stock	1,425	3,855
Excess tax benefit related to nonqualified stock options	684	2,786
Net cash provided by financing activities	1,809	6,441
Effect of foreign exchange rate on cash	41	-56
Net increase/(decrease) in cash and cash equivalents	-7,259	14,640
Cash and cash equivalents, beginning of period	82,265	89,962
Cash and cash equivalents, end of period	75,006	104,602
Supplemental disclosures of cash flow information:
Interest paid	0	13
Income taxes paid	$509	$3,168

BACKGROUND_AND_SUMMARY_OF_SIGN

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2015
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Background and Summary of Significant Accounting Policies	BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
	(a) The Company
	Globus Medical, Inc., together with its subsidiaries, is a medical device company focused on the design, development and commercialization of musculoskeletal implants. We are currently focused on implants that promote healing in patients with spine disorders. We are an engineering-driven company with a history of rapidly developing and commercializing advanced products and procedures that assist surgeons in effectively treating their patients, respond to evolving surgeon needs and address new treatment options. Since our inception in 2003, we have launched over 130 products and offer a product portfolio addressing a broad array of spinal pathologies.
	We are headquartered in Audubon, Pennsylvania, and market and sell our products through our exclusive sales force in the United States, as well as within North, Central & South America, Europe, Asia, Africa and Australia. Our sales force consists of direct sales representatives and distributor sales representatives employed by exclusive independent distributors.
	The terms “the Company,” “Globus,” “we,” “us” and “our” refer to Globus Medical, Inc. and, where applicable, our consolidated subsidiaries.
	(b) Basis of Presentation
	The accompanying interim unaudited condensed consolidated financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in complete financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying footnotes included in our Annual Report on Form 10-K for the year ended December 31, 2014.
	In the opinion of management, the statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of our financial position and of the results for the three-month periods presented. The results of operations for any interim period are not indicative of results for the full year. Certain reclassifications have been made to prior period statements to conform to the current year presentation.
	(c) Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held. All intercompany balances and transactions are eliminated in consolidation.
	(d) Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
	(e) Restricted Cash
	In December 2014, we set aside $23.4 million in cash for the payment of a portion of the Synthes and Bianco litigations. We classified this cash as restricted, as the amount was placed in escrow to be used for payment of the litigation obligations, should we not be successful with our appeals. See “Note 12. Commitments and Contingencies” below for more details regarding these litigations.
	(f) Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper, securities of U.S. government-sponsored agencies and asset-backed securities, and are classified as available-for-sale as of March 31, 2015. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
	(g) Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
	(h) Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.

ACQUISITIONS

ACQUISITIONS	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Business Combination Disclosure	ACQUISITIONS
	On February 25, 2015, we entered into an agreement to acquire Branch Medical Group, Inc. (“BMG”), a related-party manufacturer of high precision medical devices located in Audubon, PA. We closed this acquisition on March 11, 2015, for $57.0 million in cash, $5.3 million in deferred consideration, and an estimated $0.9 million payable upon finalization of closing adjustments. The amount payable to BMG on the date of acquisition of $5.2 million was also settled in connection with the acquisition.
	As previously disclosed in our definitive proxy statement, BMG had been a related-party supplier since 2005. As of February 24, 2015, David C. Paul's wife, David D. Davidar's wife, and David M. Demski collectively owned approximately 49% of the outstanding stock of BMG. In addition, since February 2010, Mr. Paul's wife and Mr. Davidar's wife had served as directors of BMG. Prior to the acquisition, we purchased products and services from BMG pursuant to a standard Supplier Quality Agreement entered into in September 2010.
	We accounted for the acquisition under the purchase method of accounting, and as a result, recorded preliminary goodwill of $40.6 million. The results of operations of BMG have been included in our results of operations from the date of acquisition. Amounts recognized for assets acquired and liabilities assumed are based on preliminary purchase price allocations and on certain management judgments. These preliminary allocations are based on an analysis of the estimated fair values of assets acquired and liabilities assumed, including identifiable tangible assets, and estimates of the useful lives of tangible assets. The final purchase price allocations will be completed after we finalize our third-party appraisal, review all available data, and complete our own internal assessments. We expect to complete our final purchase price allocations by the end of June 2015. Any additional adjustments resulting from finalization of the purchase price allocations for BMG will affect the amount assigned to goodwill. The goodwill from this acquisition is not deductible for tax purposes.
	As of March 31, 2015, we recorded the following purchase price allocation for the identifiable tangible and intangible assets and liabilities of BMG:
	(In thousands)
	Consideration:
	Cash paid at closing	$	57,042
	Deferred consideration	5,290
	Estimated closing adjustments payable	948
	Fair value of consideration	$	63,280
	Identifiable assets acquired and liabilities assumed:
	Cash acquired	$	9,027
	Accounts receivable	88
	Inventory	3,156
	Other assets	444
	Property and equipment	14,862
	Accounts payable and accrued expenses	(1,581		)
	Deferred tax liability, net	(3,293		)
	Total identifiable net assets	22,703
	Goodwill	40,577
	Total allocated purchase price	$	63,280
	The following unaudited pro forma information is based on historical data, and gives effect to our acquisition of BMG as if the acquisition had occurred on January 1, 2014. These unaudited pro forma results include adjustments having a continuing impact on our consolidated statements of income. These adjustments consist of: elimination of intercompany sales/purchase transactions and the related profit, adjustments to depreciation for the fair value and depreciable lives of property and equipment, adjustments in the capitalization of overhead costs and adjustments to tax expense based on consolidated pro forma results. These results have been prepared using assumptions our management believes are reasonable, are not necessarily indicative of the actual results that would have occurred if the acquisition had occurred on January 1, 2014, and are not necessarily indicative of the results that may be achieved in the future, including but not limited to operating synergies that we may realize as a result of the acquisition.
		Three Months Ended
	(In thousands)	March 31,			March 31,
		2015			2014
		(unaudited pro forma)
	Net sales	$	131,702		$	114,314
	Net income	24,608			21,105
	Earnings per share:
	Basic	$	0.26		$	0.23
	Diluted	$	0.26		$	0.22
	On October 23, 2014, we entered into an equity interest purchase agreement with Transplant Technologies of Texas, Ltd. (“TTOT”), an allograft tissue processor located in San Antonio, Texas, pursuant to which we acquired 100% of the equity interests for $36.1 million. In addition to the initial purchase price, we may be obligated to make milestone payments of up to $15.0 million over the next three years based primarily on sales thresholds from the product lines we acquired. We accounted for the acquisition under the purchase method of accounting in the fourth quarter of 2014. We completed our final purchase price allocation during March 2015 and the final purchase price adjustments subsequent to December 31, 2014 were not material.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	3 Months Ended
	Mar. 31, 2015
Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure	INTANGIBLE ASSETS
	A summary of intangible assets is presented below:
			March 31, 2015
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Supplier network	10	4,000		(167		)	3,833
	Customer relationships & other intangibles	7.3	5,525		(1,616		)	3,909
	Patents	17	2,420		(380		)	2,040
	Total intangible assets		$	36,505	$	(2,163	)	$	34,342
			December 31, 2014
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Supplier network	10	3,800		(88		)	3,712
	Customer relationships & other intangibles	7.3	5,525		(1,344		)	4,181
	Patents	17	2,420		(344		)	2,076
	Total intangible assets		$	36,305	$	(1,776	)	$	34,529

MARKETABLE_SECURITIES

MARKETABLE SECURITIES	3 Months Ended
	Mar. 31, 2015
Marketable Securities [Abstract]
Marketable Securities	MARKETABLE SECURITIES
	The composition of our short-term and long-term marketable securities is as follows:
			31-Mar-15
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	38,065	$	6	$	(11	)	$	38,060
	Corporate debt securities	Less than 1	57,622		18		(13		)	57,627
	Commercial paper	Less than 1	37,420		9		—			37,429
	Securities of U.S. government-sponsored agencies	Less than 1	2,999		1		—			3,000
	Asset-backed securities	Less than 1	2,159		—		(1		)	2,158
	Total short-term marketable securities		$	138,265	$	34	$	(25	)	$	138,274
	Long-term:
	Municipal bonds	2-Jan	$	27,150	$	4	$	(35	)	$	27,119
	Corporate debt securities	2-Jan	16,863		13		(2		)	16,874
	Asset-backed securities	2-Jan	19,921		9		(3		)	19,927
	Securities of U.S. government-sponsored agencies	2-Jan	7,586		7		—			7,593
	Total long-term marketable securities		$	71,520	$	33	$	(40	)	$	71,513
			31-Dec-14
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	28,684	$	2	$	(3	)	$	28,683
	Corporate debt securities	Less than 1	73,066		7		(42		)	73,031
	Commercial paper	Less than 1	44,663		8		—			44,671
	Asset-backed securities	Less than 1	54		—		—			54
	Total short-term marketable securities		$	146,467	$	17	$	(45	)	$	146,439
	Long-term:
	Municipal bonds	2-Jan	$	26,005	$	3	$	(36	)	$	25,972
	Corporate debt securities	2-Jan	19,617		3		(22		)	19,598
	Asset-backed securities	2-Jan	21,236		1		(8		)	21,229
	Securities of U.S. government-sponsored agencies	2-Jan	8,564		—		(16		)	8,548
	Total long-term marketable securities		$	75,422	$	7	$	(82	)	$	75,347

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS
	Under the accounting for fair value measurements and disclosures, fair value is defined as the price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or the liability in an orderly transaction between market participants on the measurement date. Additionally, a fair value hierarchy was established that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities and the lowest priority to unobservable inputs. The level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
	Our assets and liabilities measured at fair value on a recurring basis are classified and disclosed in one of the following three categories:
	Level 1—quoted prices (unadjusted) in active markets for identical assets and liabilities;
	Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; and
	Level 3—unobservable inputs in which there is little or no market data available, which require the reporting entity to use significant unobservable inputs or valuation techniques.
	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	March 31,		Level 1		Level 2		Level 3
		2015
	Assets
	Cash equivalents	$	12,475	$	375	$	12,100	$	—
	Municipal bonds	65,179		—		65,179		—
	Corporate debt securities	74,501		—		74,501		—
	Commercial paper	37,429		—		37,429		—
	Asset-backed securities	22,085		—		22,085		—
	Securities of U.S. government-sponsored agencies	10,593		—		10,593		—
	Liabilities
	Contingent consideration	24,843		—		—		24,843
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2014
	Assets
	Cash equivalents	$	9,802	$	1,302	$	8,500	$	—
	Municipal bonds	54,655		—		54,655		—
	Corporate debt securities	92,629		—		92,629		—
	Commercial paper	44,671		—		44,671		—
	Asset-backed securities	21,283		—		21,283		—
	Securities of U.S. government-sponsored agencies	8,548		—		8,548		—
	Liabilities
	Contingent consideration	24,335		—		—		24,335
	Contingent consideration represents our contingent milestone, performance and revenue-sharing payment obligations related to our acquisitions and is measured at fair value, based on significant inputs not observable in the market, which represents a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration uses assumptions we believe would be made by a market participant. We assess these estimates on an ongoing basis as additional data impacting the assumptions is obtained. Changes in the fair value of contingent consideration related to updated assumptions and estimates are recognized within research and development and selling, general and administrative expenses in the consolidated statements of income.

INVENTORIES

INVENTORIES	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Inventories	INVENTORIES
	(In thousands)	March 31,		December 31, 2014
		2015
	Raw materials	$	10,514	$	8,847
	Work in process	5,452		2,490
	Finished goods	82,981		79,608
	Total inventories	$	98,947	$	90,945

ACCRUED_EXPENSES

ACCRUED EXPENSES	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses	ACCRUED EXPENSES
	(In thousands)	March 31,		December 31,
		2015		2014
	Compensation and other employee-related costs	$	14,756	$	19,933
	Legal and other settlements and expenses	27,042		27,686
	Accrued non-income taxes	5,236		4,720
	Other	10,783		9,160
	Total accrued expenses	$	57,817	$	61,499

DEBT

DEBT	3 Months Ended
	Mar. 31, 2015
Debt Disclosure [Abstract]
Debt	DEBT
	Line of Credit
	In May 2011, we entered into a credit agreement with Wells Fargo Bank related to a revolving credit facility that provided for borrowings up to $50.0 million. At our request, and with the approval of the bank, the amount of borrowings available under the revolving credit facility can be increased to $75.0 million. The revolving credit facility includes up to a $25.0 million sub-limit for letters of credit. Cash advances bear interest at our option either at a fluctuating rate per annum equal to the daily LIBOR in effect for a one-month period plus 0.75%, or a fixed rate for a one- or three-month period equal to LIBOR plus 0.75%. The credit agreement governing the revolving credit facility also subjects us to various restrictive covenants, including the requirement to maintain maximum consolidated leverage. The covenants also include limitations on our ability to repurchase shares, to pay cash dividends or to enter into a sale transaction. As of March 31, 2015, we were in compliance with all covenants under the credit agreement, there were no outstanding borrowings under the revolving credit facility and available borrowings were $50.0 million. We may terminate the credit agreement at any time on ten days’ notice without premium or penalty.
	Subsequent to March 31, 2015, we amended the above credit agreement with Wells Fargo Bank, extending the term of the revolving credit facility from May 2015 to May 2016. No other terms were modified.

EQUITY

EQUITY	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Equity	EQUITY
	Our amended and restated Certificate of Incorporation provides for a total of 785,000,000 authorized shares of common stock. Of the authorized number of shares of common stock, 500,000,000 shares are designated as Class A common stock (“Class A Common”), 275,000,000 shares are designated as Class B common stock (“Class B Common”) and 10,000,000 shares are designated as Class C common stock (“Class C Common”).
	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common			Class B		Total
					Common
	March 31, 2015	71,022,427			23,877,556		94,899,983
	December 31, 2014	70,828,187			23,877,556		94,705,743
	The following table summarizes changes in total equity:
		Three Months Ended
	(In thousands)	March 31,
		2015
	Total equity, beginning of period	$	585,454
	Net income	24,648
	Stock-based compensation	2,131
	Exercise of stock options	1,425
	Excess tax benefit of nonqualified stock options	684
	Other comprehensive loss	(178		)
	Total equity, end of period	$	614,164
	The tables below present the changes in each component of accumulated other comprehensive income/(loss), including current period other comprehensive income/(loss) and reclassifications out of accumulated other comprehensive income/(loss):
	(In thousands)			Unrealized gain/(loss) on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive loss, net of tax, at December 31, 2014			$	(64	)	$	(1,593	)	$	(1,657	)
	Other comprehensive income/(loss) before reclassifications			64			(243		)	(179		)
	Amounts reclassified from accumulated other comprehensive income, net of tax			1			—			1
	Other comprehensive income/(loss), net of tax			65			(243		)	(178		)
	Accumulated other comprehensive income/(loss), net of tax, at March 31, 2015			$	1		$	(1,836	)	$	(1,835	)
	(In thousands)			Unrealized gain/(loss) on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive income/(loss), net of tax, at December 31, 2013			$	32		$	(1,041	)	$	(1,009	)
	Other comprehensive loss before reclassifications			(5		)	(3		)	(8		)
	Amounts reclassified from accumulated other comprehensive loss, net of tax			6			—			6
	Other comprehensive income/(loss), net of tax			1			(3		)	(2		)
	Accumulated other comprehensive income/(loss), net of tax, at March 31, 2014			$	33		$	(1,044	)	$	(1,011	)

STOCKBASED_COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	STOCK-BASED COMPENSATION
	We have three stock plans: our Amended and Restated 2003 Stock Plan, our 2008 Stock Plan, and our 2012 Equity Incentive Plan (the “2012 Plan”).  The 2012 Plan is the only remaining active stock plan. The purpose of these stock plans was, and the 2012 Plan is, to provide incentive to employees, directors, and consultants of Globus.  The Plans are administered by the Board of Directors of Globus (the “Board”) or its delegates. The number, type of option, exercise price, and vesting terms are determined by the Board or its delegates in accordance with the terms of the Plans. The options granted expire on a date specified by the Board, but generally not more than ten years from the grant date. Option grants to employees generally vest in varying installments over a four-year period.
	The 2012 Plan was approved by our Board in March 2012, and by our stockholders in June 2012. Under the 2012 Plan, the aggregate number of shares of Class A Common stock that may be issued subject to options and other awards is equal to the sum of (i) 3,076,923 shares, (ii) any shares available for issuance under the 2008 Plan as of March 13, 2012, (iii) any shares underlying awards outstanding under the 2008 Plan as of March 13, 2012 that, on or after that date, are forfeited, terminated, expired or lapse for any reason, or are settled for cash without delivery of shares and (iv) starting January 1, 2013, an annual increase in the number of shares available under the 2012 Plan equal to up to 3% of the number of shares of our common and preferred stock outstanding at the end of the previous year, as determined by our Board. The number of shares that may be issued or transferred pursuant to incentive stock options under the 2012 Plan is limited to 10,769,230 shares. The shares of Class A Common stock covered by the 2012 Plan are authorized but unissued shares, treasury shares or shares of common stock purchased on the open market.
	As of March 31, 2015, there were 4,958,899 shares of Class A Common stock available for future grants under the 2012 Plan.
	The weighted average grant date per share fair values of the options awarded to employees were as follows:
		Three Months Ended
		March 31,			March 31,
		2015			2014
	Weighted average grant date per share fair value	$	9.42		$	10.34
	Stock option activity during the three months ended March 31, 2015 is summarized as follows:
		Option Shares(thousands)		Weighted average exercise price			Weighted average remaining contractual life (years)	Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2014	4,854		$	14.5
	Granted	1,159		23.98
	Exercised	(194	)	7.34
	Forfeited	(98	)	16.23
	Outstanding at March 31, 2015	5,721		$	16.63		7.6	$	49,236
	Exercisable at March 31, 2015	2,569		$	10.77		5.7	$	37,164
	Expected to vest at March 31, 2015	3,152		$	21.41		9.1	$	12,073
	Compensation expense related to stock options granted to employees and non-employees under our stock plans and the intrinsic value of stock options exercised was as follows:
		Three Months Ended
	(In thousands)	March 31,			March 31,
		2015			2014
	Compensation expense related to stock options	$	2,131		$	1,927
	Intrinsic value of stock options exercised	3,260			11,283
	As of March 31, 2015, there was $24.2 million of unrecognized compensation expense related to unvested employee stock options that are expected to vest over a weighted average period of three years.

INCOME_TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES
	In computing our income tax provision, we make certain estimates and management judgments, such as estimated annual taxable income or loss, annual effective tax rate, the nature and timing of permanent and temporary differences between taxable income for financial reporting and tax reporting, and the recoverability of deferred tax assets. Our estimates and assumptions may change as new events occur, additional information is obtained, or as the tax environment changes. Should facts and circumstances change during a quarter causing a material change to the estimated effective income tax rate, a cumulative adjustment is recorded.
		Three Months Ended
		March 31,		March 31,
		2015		2014
	Effective income tax rate	35.4	%	34.9	%
	The nominal change in the effective income tax rate between the current year and prior year periods is due primarily to changes in the components of taxable income.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES
	We are involved in a number of proceedings, legal actions, and claims. Such matters are subject to many uncertainties, and the outcomes of these matters are not within our control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions prohibiting us from engaging in certain activities, which, if granted, could require significant expenditures and/or result in lost revenues. We record a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded. While it is not possible to predict the outcome for most of the matters discussed, we believe it is possible that costs associated with them could have a material adverse impact on our consolidated earnings, financial position or cash flows.
	N-Spine, Synthes and DePuy Synthes Litigation
	In April 2010, N-Spine, Inc. and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. N-Spine, the patent owner, and Synthes USA, a licensee of the subject patent, allege that we infringe one or more claims of the patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. N-Spine and Synthes USA seek injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. This matter was stayed on July 14, 2011 pending the resolution of an inter partes reexamination on the asserted patent granted by the U.S. Patent and Trademark Office (“USPTO”) in February 2011. In December 2011, the examiner withdrew the original grounds of rejection of the asserted patent and we have appealed the examiner’s decision. In January 2014, the USPTO ruled on the appeal finding certain claims rejected in view of the prior art and affirming certain other claims. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	In a related matter, on January 8, 2014, Depuy Synthes Products, LLC (“Depuy Synthes”) filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Depuy Synthes alleges that we infringe one or more claims of the asserted patent by making, using, offering for sale or selling our TRANSITION® stabilization system product. Depuy Synthes seeks injunctive relief and an unspecified amount in damages. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC Litigation
	In July 2011, Synthes USA, LLC, Synthes USA Products, LLC and Synthes USA Sales, LLC filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. Synthes USA LLC, the patent owner, Synthes USA Products, LLC, a licensee to manufacture products of the subject patents, and Synthes USA Sales LLC, a licensee to sell products of the subject patents, allege that we infringed one or more claims of three patents by making, using, offering for sale or selling our COALITION®, INDEPENDENCE® and INTERCONTINENTAL® products. As a result of the acquisition of Synthes, Inc. by Johnson & Johnson, a motion was filed to change the plaintiff in this matter to DePuy Synthes in February 2013. On June 14, 2013, the jury in this case returned a verdict, finding that prior versions of the three products we previously sold did infringe on DePuy Synthes’ patents and awarding monetary damages in the amount of $16.0 million. The jury also upheld the validity of DePuy Synthes’ patents. There was no finding of willful infringement by Globus.
	This verdict does not impact our ability to conduct our business or have any material impact on our future revenues. As this lawsuit involved only three products that are no longer part of our product portfolio, this verdict is not expected to impair our ability to sell any of our future products.
	We believe the facts and the law do not support the jury’s findings of infringement and patent validity and are seeking to overturn the verdict through the appeals process.
	For the year ended December 31, 2013, we recorded $19.5 million in damages and other litigation-related costs related to this case, of which $1.3 million was included in provision for litigation - cost of goods sold (due to a write off of certain inventory which will not be sold due to the verdict) and $18.2 million was included in provision for litigation (operating expense). During the year ended December 31, 2014, we accrued an additional $0.6 million in interest included in provision for litigation related to this litigation.
	L5 Litigation
	In December 2009, we filed suit in the Court of Common Pleas of Montgomery County, Pennsylvania against our former exclusive independent distributor L5 Surgical, LLC and its principals, seeking an injunction and declaratory judgment concerning certain restrictive covenants made to L5 by its sales representatives. L5 brought counterclaims against us alleging tortious interference, unfair competition and conspiracy. The injunction phase was resolved in September 2010, and this matter is now in the discovery phase of litigation on the underlying damages claims. We intend to defend our rights vigorously. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	NuVasive Litigation
	In October 2010, NuVasive, Inc. filed suit against us in the U.S. District Court for the District of Delaware for patent infringement. NuVasive, the patent owner, alleges that we infringe one or more claims of three patents by making, using, offering for sale or selling our MARS 3V™ retractor for use in certain lateral fusion procedures. NuVasive sought injunctive relief and an unspecified amount in damages. This matter was settled on February 12, 2015 for an undisclosed amount that was not material.
	NuVasive Employee Litigation
	We have hired several employees who were formerly employed by NuVasive, Inc. In July 2011, NuVasive filed suit against us in the District Court of Travis County, Texas alleging that our hiring of one named former employee and other unnamed former employees constitutes tortious interference with its contracts with those employees, and with prospective business relationships, as well as aiding and abetting the breach of fiduciary duty. NuVasive sought compensatory damages, permanent injunction, punitive damages and attorneys’ fees. This matter was settled on February 12, 2015 for an undisclosed amount that was not material.
	Bianco Litigation
	On March 21, 2012, Sabatino Bianco filed suit against us in the Federal District Court for the Eastern District of Texas claiming that we misappropriated his trade secret and confidential information and improperly utilized it in developing our CALIBER® product. Bianco alleges that we engaged in misappropriation of trade secrets, breach of contract, unfair competition, fraud and theft and seeks correction of inventorship, injunctive relief and exemplary damages. On April 20, 2012, Bianco filed a motion for a preliminary injunction, seeking to enjoin us from making, using, selling, importing or offering for sale our CALIBER® product. On November 15, 2012, the court denied Bianco’s motion for preliminary injunction. On October 1, 2013, Bianco amended his complaint to claim that his trade secrets and confidential information were also used improperly in developing our RISE® and CALIBER-L® products.
	On January 17, 2014, the jury in this case returned a verdict in favor of Bianco on a claim of misappropriation of trade secret. We accrued the verdict amount of $4.3 million as of December 31, 2013. The jury found against Bianco on the claims of breach of contract and disgorgement of profits. The court granted our motion for judgment as a matter of law and dismissed Bianco’s claims for unfair competition, fraud, and exemplary damages, and Bianco abandoned the claim of misappropriation of confidential information. Bianco’s claims of correction of inventorship, unjust enrichment, and permanent injunctive relief were not submitted to the jury. On March 7, 2014, the court denied Bianco’s claim for correction of inventorship and ruled he is not entitled to be named as a co-inventor on any of the patents at issue, and also denied his claim for unjust enrichment. On March 17, 2014, the court denied Bianco’s claim for permanent injunctive relief. On July 2, 2014, the court awarded Bianco an ongoing royalty of 5% of the net sales of the CALIBER®, CALIBER®-L, and RISE® products, or products that are not colorably different from those products, for a fifteen year period on sales starting on January 18, 2014. The court entered final judgment on the jury verdict on July 17, 2014. Post-trial motions were denied on October 27, 2014 and the matter is currently on appeal.
	We do not expect the verdict to impact our ability to conduct our business or to have any material impact on our future revenues. We believe the facts and the law do not support the jury’s findings of misappropriation of trade secret and are seeking to overturn the verdict through the appeals process.
	Altus Partners, LLC Litigation
	On February 20, 2013, Altus Partners, LLC filed suit against us in the U.S. District Court for the Eastern District of Pennsylvania for patent infringement. On April 7, 2014, we settled the litigation with Altus Partners and recognized a provision for litigation of $2.0 million.
	Bonutti Skeletal Innovations, LLC Litigation
	On November 19, 2014, Bonutti Skeletal Innovations, LLC filed suit against us in the U.S. District Court for the Eastern District of Pennsylvania for patent infringement. Bonutti Skeletal, a non-practicing entity, alleges that Globus willfully infringes one or more claims of six patents by making, using, offering for sale or selling the CALIBER®, CALIBER®-L, COALITION®, CONTINENTAL®, FORGE®, FORTIFY®, INDEPENDENCE®, INTERCONTINENTAL®, MONUMENT®, NIKO®, RISE®, SIGNATURE®, SUSTAIN®, and TRANSCONTINENTAL® products. Bonutti Skeletal seeks an unspecified amount in damages and injunctive relief. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	Flexuspine, Inc. Litigation
	On March 11, 2015, Flexuspine, Inc. filed suit against us in the U.S. District Court for the Eastern District of Texas for patent infringement. Flexuspine, Inc. alleges that Globus willfully infringes one or more claims of five patents by making, using, offering for sale or selling the CALIBER®, CALIBER®-L, RISE®, RISE®-L, RISE® INTRALIF®, and ALTERA® products. Flexuspine seeks an unspecified amount in damages and injunctive relief. The probable outcome of this litigation cannot be determined, nor can we estimate a range of potential loss. Therefore, in accordance with authoritative guidance on the evaluation of loss contingencies, we have not recorded an accrual related to this litigation.
	In addition, we are subject to legal proceedings arising in the ordinary course of business.

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Related-Party Transactions	RELATED-PARTY TRANSACTIONS
	Prior to March 11, 2015, we had contracted with BMG, which at the time was a related-party manufacturer. We have purchased the following amounts of products and services from BMG:
		Period		Three Months Ended
		Ended
	(In thousands)	March 11,		March 31,
		2015		2014
	Purchases from related-party supplier	$	5,304	$	4,850
	On March 11, 2015, BMG was acquired by Globus, and therefore as of March 31, 2015, there are no further amounts payable to BMG. As of December 31, 2014, we had $5.4 million of accounts payable due to BMG. The amount payable to BMG on the date of acquisition of $5.2 million was settled in connection with the acquisition.

SEGMENT_AND_GEOGRAPHIC_INFORMA

SEGMENT AND GEOGRAPHIC INFORMATION	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Segment And Geographic Information	SEGMENT AND GEOGRAPHIC INFORMATION
	Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. We globally manage the business within one reportable segment. Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Products are sold principally in the United States.
	The following table represents total sales by geographic area, based on the location of the customer:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2015		2014
	United States	$	119,983	$	101,705
	International	11,621		12,505
	Total sales	$	131,604	$	114,210
	We classify our products into two categories: innovative fusion products and disruptive technology products. The following table represents total sales by product category:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2015		2014
	Innovative Fusion	$	70,370	$	66,770
	Disruptive Technology	61,234		47,440
	Total sales	$	131,604	$	114,210

BACKGROUND_AND_SUMMARY_OF_SIGN1

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2015
BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Principles of Consolidation	Principles of Consolidation
	The accompanying consolidated financial statements include the accounts of Globus and its wholly-owned subsidiaries. Our consolidation policy requires the consolidation of entities where a controlling financial interest is held. All intercompany balances and transactions are eliminated in consolidation.
Use of Estimates	Use of Estimates
	The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ materially from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.
	Significant areas that require management’s estimates include intangible assets, contingent payment liabilities, allowance for doubtful accounts, stock-based compensation, provision for excess and obsolete inventory, useful lives of assets, the outcome of litigation, and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results.
Marketable Securities	Marketable Securities
	Our marketable securities include municipal bonds, corporate debt securities, commercial paper, securities of U.S. government-sponsored agencies and asset-backed securities, and are classified as available-for-sale as of March 31, 2015. Available-for-sale securities are recorded at fair value in both short-term and long-term marketable securities on our consolidated balance sheets. The change in fair value for available-for-sale securities is recorded, net of taxes, as a component of accumulated other comprehensive income on our consolidated balance sheets. Premiums and discounts are recognized over the life of the related security as an adjustment to yield using the straight-line method. Realized gains or losses from the sale of our marketable securities are determined on a specific identification basis. Realized gains and losses, along with interest income and the amortization/accretion of premiums/discounts are included as a component of other income, net, on our consolidated statements of income. Interest receivable is recorded as a component of prepaid expenses and other current assets on our consolidated balance sheets.
	We maintain a portfolio of various holdings, types and maturities, though most of the securities in our portfolio could be liquidated at minimal cost at any time. We invest in securities that meet or exceed standards as defined in our investment policy. Our policy also limits the amount of credit exposure to any one issue, issuer or type of security. We review our securities for other-than-temporary impairment at each reporting period. If an unrealized loss for any security is considered to be other-than-temporary, the loss will be recognized in our consolidated statement of income in the period the determination is made.
Inventories	Inventories
	Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The majority of our inventories are finished goods as we mainly utilize third-party suppliers to source our products. We periodically evaluate the carrying value of our inventories in relation to our estimated forecast of product demand, which takes into consideration the estimated life cycle of product releases. When quantities on hand exceed estimated sales forecasts, we record a reserve for such excess inventories.
Revenue Recognition	Revenue Recognition
	Revenue is recognized when persuasive evidence of an arrangement exists, product delivery has occurred, pricing is fixed or determinable, and collection is reasonably assured. A significant portion of our revenue is generated from consigned inventory maintained at hospitals or with sales representatives. For these products, revenue is recognized at the time the product is used or implanted. For all other transactions, we recognize revenue when title to the goods and risk of loss transfer to customers, provided there are no remaining performance obligations that will affect the customer’s final acceptance of the sale. Our policy is to classify shipping and handling costs billed to customers as sales and the related expenses as cost of goods sold.

ACQUISITIONS_Tables

ACQUISITIONS (Tables)	3 Months Ended
	Mar. 31, 2015
Business Combinations [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	As of March 31, 2015, we recorded the following purchase price allocation for the identifiable tangible and intangible assets and liabilities of BMG:
	(In thousands)
	Consideration:
	Cash paid at closing	$	57,042
	Deferred consideration	5,290
	Estimated closing adjustments payable	948
	Fair value of consideration	$	63,280
	Identifiable assets acquired and liabilities assumed:
	Cash acquired	$	9,027
	Accounts receivable	88
	Inventory	3,156
	Other assets	444
	Property and equipment	14,862
	Accounts payable and accrued expenses	(1,581		)
	Deferred tax liability, net	(3,293		)
	Total identifiable net assets	22,703
	Goodwill	40,577
	Total allocated purchase price	$	63,280
Business Acquisition, Pro Forma Information	These results have been prepared using assumptions our management believes are reasonable, are not necessarily indicative of the actual results that would have occurred if the acquisition had occurred on January 1, 2014, and are not necessarily indicative of the results that may be achieved in the future, including but not limited to operating synergies that we may realize as a result of the acquisition.
		Three Months Ended
	(In thousands)	March 31,			March 31,
		2015			2014
		(unaudited pro forma)
	Net sales	$	131,702		$	114,314
	Net income	24,608			21,105
	Earnings per share:
	Basic	$	0.26		$	0.23
	Diluted	$	0.26		$	0.22

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	3 Months Ended
	Mar. 31, 2015
Intangible Assets Disclosure [Abstract]
Intangible Assets Acquired as Part of Business Combination	A summary of intangible assets is presented below:
			March 31, 2015
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Supplier network	10	4,000		(167		)	3,833
	Customer relationships & other intangibles	7.3	5,525		(1,616		)	3,909
	Patents	17	2,420		(380		)	2,040
	Total intangible assets		$	36,505	$	(2,163	)	$	34,342
			December 31, 2014
	(In thousands)	Weighted	Gross		Accumulated Amortization			Intangible
		Average Amortization	Carrying					Assets, net
		Period	Amount
		(in years)
	In-process research & development	—	$	24,560	$	—		$	24,560
	Supplier network	10	3,800		(88		)	3,712
	Customer relationships & other intangibles	7.3	5,525		(1,344		)	4,181
	Patents	17	2,420		(344		)	2,076
	Total intangible assets		$	36,305	$	(1,776	)	$	34,529

MARKETABLE_SECURITIES_Tables

MARKETABLE SECURITIES (Tables)	3 Months Ended
	Mar. 31, 2015
Marketable Securities [Abstract]
Marketable Securities	The composition of our short-term and long-term marketable securities is as follows:
			31-Mar-15
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	38,065	$	6	$	(11	)	$	38,060
	Corporate debt securities	Less than 1	57,622		18		(13		)	57,627
	Commercial paper	Less than 1	37,420		9		—			37,429
	Securities of U.S. government-sponsored agencies	Less than 1	2,999		1		—			3,000
	Asset-backed securities	Less than 1	2,159		—		(1		)	2,158
	Total short-term marketable securities		$	138,265	$	34	$	(25	)	$	138,274
	Long-term:
	Municipal bonds	2-Jan	$	27,150	$	4	$	(35	)	$	27,119
	Corporate debt securities	2-Jan	16,863		13		(2		)	16,874
	Asset-backed securities	2-Jan	19,921		9		(3		)	19,927
	Securities of U.S. government-sponsored agencies	2-Jan	7,586		7		—			7,593
	Total long-term marketable securities		$	71,520	$	33	$	(40	)	$	71,513
			31-Dec-14
	(In thousands)	Contractual Maturity	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value
		(in years)
	Short-term:
	Municipal bonds	Less than 1	$	28,684	$	2	$	(3	)	$	28,683
	Corporate debt securities	Less than 1	73,066		7		(42		)	73,031
	Commercial paper	Less than 1	44,663		8		—			44,671
	Asset-backed securities	Less than 1	54		—		—			54
	Total short-term marketable securities		$	146,467	$	17	$	(45	)	$	146,439
	Long-term:
	Municipal bonds	2-Jan	$	26,005	$	3	$	(36	)	$	25,972
	Corporate debt securities	2-Jan	19,617		3		(22		)	19,598
	Asset-backed securities	2-Jan	21,236		1		(8		)	21,229
	Securities of U.S. government-sponsored agencies	2-Jan	8,564		—		(16		)	8,548
	Total long-term marketable securities		$	75,422	$	7	$	(82	)	$	75,347

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis	The fair value of our assets and liabilities measured at fair value on a recurring basis was as follows:
		Balance at
	(In thousands)	March 31,		Level 1		Level 2		Level 3
		2015
	Assets
	Cash equivalents	$	12,475	$	375	$	12,100	$	—
	Municipal bonds	65,179		—		65,179		—
	Corporate debt securities	74,501		—		74,501		—
	Commercial paper	37,429		—		37,429		—
	Asset-backed securities	22,085		—		22,085		—
	Securities of U.S. government-sponsored agencies	10,593		—		10,593		—
	Liabilities
	Contingent consideration	24,843		—		—		24,843
		Balance at
	(In thousands)	December 31,		Level 1		Level 2		Level 3
		2014
	Assets
	Cash equivalents	$	9,802	$	1,302	$	8,500	$	—
	Municipal bonds	54,655		—		54,655		—
	Corporate debt securities	92,629		—		92,629		—
	Commercial paper	44,671		—		44,671		—
	Asset-backed securities	21,283		—		21,283		—
	Securities of U.S. government-sponsored agencies	8,548		—		8,548		—
	Liabilities
	Contingent consideration	24,335		—		—		24,335

INVENTORIES_Tables

INVENTORIES (Tables)	3 Months Ended
	Mar. 31, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory
	(In thousands)	March 31,		December 31, 2014
		2015
	Raw materials	$	10,514	$	8,847
	Work in process	5,452		2,490
	Finished goods	82,981		79,608
	Total inventories	$	98,947	$	90,945

ACCRUED_EXPENSES_Tables

ACCRUED EXPENSES (Tables)	3 Months Ended
	Mar. 31, 2015
Payables and Accruals [Abstract]
Accrued Expenses
	(In thousands)	March 31,		December 31,
		2015		2014
	Compensation and other employee-related costs	$	14,756	$	19,933
	Legal and other settlements and expenses	27,042		27,686
	Accrued non-income taxes	5,236		4,720
	Other	10,783		9,160
	Total accrued expenses	$	57,817	$	61,499

EQUITY_Tables

EQUITY (Tables)	3 Months Ended
	Mar. 31, 2015
Equity [Abstract]
Schedule of Issued and Outstanding Shares by Class	Our issued and outstanding common shares by Class were as follows:
	(Shares)	Class A Common			Class B	Total
					Common
	March 31, 2015	71,022,427			23,877,556	94,899,983
	December 31, 2014	70,828,187			23,877,556	94,705,743
Schedule of Stockholders Equity	The following table summarizes changes in total equity:
		Three Months Ended
	(In thousands)	March 31,
		2015
	Total equity, beginning of period	$	585,454
	Net income	24,648
	Stock-based compensation	2,131
	Exercise of stock options	1,425
	Excess tax benefit of nonqualified stock options	684
	Other comprehensive loss	(178		)
	Total equity, end of period	$	614,164

EQUITY_Accumulated_Other_Compr

EQUITY Accumulated Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2015
Accumulated Other Comprehensive Income [Abstract]
Accumulated Other Comprehensive Income/(Loss), Net of Tax	The tables below present the changes in each component of accumulated other comprehensive income/(loss), including current period other comprehensive income/(loss) and reclassifications out of accumulated other comprehensive income/(loss):
	(In thousands)	Unrealized gain/(loss) on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive loss, net of tax, at December 31, 2014	$	(64	)	$	(1,593	)	$	(1,657	)
	Other comprehensive income/(loss) before reclassifications	64			(243		)	(179		)
	Amounts reclassified from accumulated other comprehensive income, net of tax	1			—			1
	Other comprehensive income/(loss), net of tax	65			(243		)	(178		)
	Accumulated other comprehensive income/(loss), net of tax, at March 31, 2015	$	1		$	(1,836	)	$	(1,835	)
	(In thousands)	Unrealized gain/(loss) on marketable securities, net of tax			Foreign currency translation adjustments			Accumulated other comprehensive loss
	Accumulated other comprehensive income/(loss), net of tax, at December 31, 2013	$	32		$	(1,041	)	$	(1,009	)
	Other comprehensive loss before reclassifications	(5		)	(3		)	(8		)
	Amounts reclassified from accumulated other comprehensive loss, net of tax	6			—			6
	Other comprehensive income/(loss), net of tax	1			(3		)	(2		)
	Accumulated other comprehensive income/(loss), net of tax, at March 31, 2014	$	33		$	(1,044	)	$	(1,011	)

STOCKBASED_COMPENSATION_Tables

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Grants in Period, Weighted Average Grant Date Fair Value	The weighted average grant date per share fair values of the options awarded to employees were as follows:
		Three Months Ended
		March 31,			March 31,
		2015			2014
	Weighted average grant date per share fair value	$	9.42		$	10.34
Summary of Stock Option Activity	Stock option activity during the three months ended March 31, 2015 is summarized as follows:
		Option Shares(thousands)		Weighted average exercise price			Weighted average remaining contractual life (years)	Aggregate intrinsic value (thousands)
	Outstanding at December 31, 2014	4,854		$	14.5
	Granted	1,159		23.98
	Exercised	(194	)	7.34
	Forfeited	(98	)	16.23
	Outstanding at March 31, 2015	5,721		$	16.63		7.6	$	49,236
	Exercisable at March 31, 2015	2,569		$	10.77		5.7	$	37,164
	Expected to vest at March 31, 2015	3,152		$	21.41		9.1	$	12,073
Stock Option Compensation Expense and Intrinsic Value Schedule	Compensation expense related to stock options granted to employees and non-employees under our stock plans and the intrinsic value of stock options exercised was as follows:
		Three Months Ended
	(In thousands)	March 31,			March 31,
		2015			2014
	Compensation expense related to stock options	$	2,131		$	1,927
	Intrinsic value of stock options exercised	3,260			11,283

INCOME_TAXES_Tables

INCOME TAXES (Tables)	3 Months Ended
	Mar. 31, 2015
Income Tax Disclosure [Abstract]
Effective income tax rate
		Three Months Ended
		March 31,		March 31,
		2015		2014
	Effective income tax rate	35.4	%	34.9	%

RELATEDPARTY_TRANSACTIONS_Tabl

RELATED-PARTY TRANSACTIONS (Tables)	3 Months Ended
	Mar. 31, 2015
Related Party Transactions [Abstract]
Schedule of Related-Party Transactions	We have purchased the following amounts of products and services from BMG:
		Period		Three Months Ended
		Ended
	(In thousands)	March 11,		March 31,
		2015		2014
	Purchases from related-party supplier	$	5,304	$	4,850

SEGMENT_AND_GEOGRAPHIC_INFORMA1

SEGMENT AND GEOGRAPHIC INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2015
Segment Reporting [Abstract]
Schedule of Revenue from External Customers by Geographical Area	The following table represents total sales by geographic area, based on the location of the customer:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2015		2014
	United States	$	119,983	$	101,705
	International	11,621		12,505
	Total sales	$	131,604	$	114,210
Revenue from External Customers by Products and Services	The following table represents total sales by product category:
		Three Months Ended
	(In thousands)	March 31,		March 31,
		2015		2014
	Innovative Fusion	$	70,370	$	66,770
	Disruptive Technology	61,234		47,440
	Total sales	$	131,604	$	114,210

BACKGROUND_AND_SUMMARY_OF_SIGN2

BACKGROUND AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Summary of Significant Accounting Policies
Restricted cash	$23,370	$23,370
Minimum
Summary of Significant Accounting Policies
Number of Products Launched Since Inception	130

ACQUISITIONS_Details

ACQUISITIONS (Details) (USD $)	12 Months Ended	3 Months Ended
	Dec. 31, 2014	Mar. 31, 2015	Mar. 11, 2015	Oct. 23, 2014
Business Acquisition
Accounts payable to related-party	$5,359,000	$0	$5,200,000
Goodwill	53,196,000	93,573,000
Acquisition 2014
Business Acquisition
Payments to Acquire Businesses, Gross	36,100,000
Range of undiscounted aggregate contingent consideration from acquisitions, maximum				15,000,000
Acquisition 2015
Business Acquisition
Payments to Acquire Businesses, Gross		57,042,000
Deferred consideration		5,290,000
Estimated closing adjustments payable		948,000
Related party ownership percentage			49.00%
Cash acquired			9,027,000
Accounts receivable			88,000
Inventory			3,156,000
Other assets			444,000
Property and equipment			14,862,000
Accounts payable and accrued expenses			-1,581,000
Deferred tax liability, net			-3,293,000
Total identifiable net assets			22,703,000
Goodwill			40,577,000
Total allocated purchase price			$63,280,000

ACQUISITIONS_Proforma_Details

ACQUISITIONS Proforma (Details) (Acquisition 2015, USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Acquisition 2015
Net sales	$131,702	$114,314
Net income	$24,608	$21,105
Basic	$0.26	$0.23
Diluted	$0.26	$0.22

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Acquired Intangible Assets
Intangible assets, gross	$36,505	$36,305
Accumulated amortization	-2,163	-1,776
Intangible assets, net	34,342	34,529
Supplier Network
Acquired Intangible Assets
Weighted average amortization period	10 years	10 years
Gross carrying amount	4,000	3,800
Accumulated amortization	-167	-88
Finite-lived intangible assets, net	3,833	3,712
Customer Relationships & Other Intangibles
Acquired Intangible Assets
Weighted average amortization period	7 years 3 months	7 years 3 months
Gross carrying amount	5,525	5,525
Accumulated amortization	-1,616	-1,344
Finite-lived intangible assets, net	3,909	4,181
Patents
Acquired Intangible Assets
Weighted average amortization period	17 years	17 years
Gross carrying amount	2,420	2,420
Accumulated amortization	-380	-344
Finite-lived intangible assets, net	2,040	2,076
In-Process Research & Development
Acquired Intangible Assets
Indefinite-lived intangible assets	$24,560	$24,560

MARKETABLE_SECURITIES_Details

MARKETABLE SECURITIES (Details) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Dec. 31, 2014
Short-term Marketable Securities
Schedule of Marketable Securities
Amortized Cost	138,265	146,467
Gross Unrealized Gains	34	17
Gross Unrealized Losses	-25	-45
Fair Value	138,274	146,439
Short-term Marketable Securities | Municipal Bonds
Schedule of Marketable Securities
Amortized Cost	38,065	28,684
Gross Unrealized Gains	6	2
Gross Unrealized Losses	-11	-3
Fair Value	38,060	28,683
Short-term Marketable Securities | Municipal Bonds | Maximum
Schedule of Marketable Securities
Contractual Maturity	1 year	1 year
Short-term Marketable Securities | Corporate Debt Securities
Schedule of Marketable Securities
Amortized Cost	57,622	73,066
Gross Unrealized Gains	18	7
Gross Unrealized Losses	-13	-42
Fair Value	57,627	73,031
Short-term Marketable Securities | Corporate Debt Securities | Maximum
Schedule of Marketable Securities
Contractual Maturity	1 year	1 year
Short-term Marketable Securities | Commercial Paper
Schedule of Marketable Securities
Amortized Cost	37,420	44,663
Gross Unrealized Gains	9	8
Gross Unrealized Losses	0	0
Fair Value	37,429	44,671
Short-term Marketable Securities | Commercial Paper | Maximum
Schedule of Marketable Securities
Contractual Maturity	1 year	1 year
Short-term Marketable Securities | Asset-backed Securities
Schedule of Marketable Securities
Amortized Cost	2,159	54
Gross Unrealized Gains	0	0
Gross Unrealized Losses	-1	0
Fair Value	2,158	54
Short-term Marketable Securities | Asset-backed Securities | Maximum
Schedule of Marketable Securities
Contractual Maturity	1 year	1 year
Short-term Marketable Securities | Securities of U.S. government-sponsored agencies
Schedule of Marketable Securities
Amortized Cost	2,999
Gross Unrealized Gains	1
Gross Unrealized Losses	0
Fair Value	3,000
Short-term Marketable Securities | Securities of U.S. government-sponsored agencies | Maximum
Schedule of Marketable Securities
Contractual Maturity	1 year
Long-term Marketable Securities
Schedule of Marketable Securities
Amortized Cost	71,520	75,422
Gross Unrealized Gains	33	7
Gross Unrealized Losses	-40	-82
Fair Value	71,513	75,347
Long-term Marketable Securities | Municipal Bonds
Schedule of Marketable Securities
Amortized Cost	27,150	26,005
Gross Unrealized Gains	4	3
Gross Unrealized Losses	-35	-36
Fair Value	27,119	25,972
Long-term Marketable Securities | Municipal Bonds | Minimum
Schedule of Marketable Securities
Contractual Maturity	1 year	1 year
Long-term Marketable Securities | Municipal Bonds | Maximum
Schedule of Marketable Securities
Contractual Maturity	2 years	2 years
Long-term Marketable Securities | Corporate Debt Securities
Schedule of Marketable Securities
Amortized Cost	16,863	19,617
Gross Unrealized Gains	13	3
Gross Unrealized Losses	-2	-22
Fair Value	16,874	19,598
Long-term Marketable Securities | Corporate Debt Securities | Minimum
Schedule of Marketable Securities
Contractual Maturity	1 year	1 year
Long-term Marketable Securities | Corporate Debt Securities | Maximum
Schedule of Marketable Securities
Contractual Maturity	2 years	2 years
Long-term Marketable Securities | Asset-backed Securities
Schedule of Marketable Securities
Amortized Cost	19,921	21,236
Gross Unrealized Gains	9	1
Gross Unrealized Losses	-3	-8
Fair Value	19,927	21,229
Long-term Marketable Securities | Asset-backed Securities | Minimum
Schedule of Marketable Securities
Contractual Maturity	1 year	1 year
Long-term Marketable Securities | Asset-backed Securities | Maximum
Schedule of Marketable Securities
Contractual Maturity	2 years	2 years
Long-term Marketable Securities | Securities of U.S. government-sponsored agencies
Schedule of Marketable Securities
Amortized Cost	7,586	8,564
Gross Unrealized Gains	7	0
Gross Unrealized Losses	0	-16
Fair Value	7,593	8,548
Long-term Marketable Securities | Securities of U.S. government-sponsored agencies | Minimum
Schedule of Marketable Securities
Contractual Maturity	1 year	1 year
Long-term Marketable Securities | Securities of U.S. government-sponsored agencies | Maximum
Schedule of Marketable Securities
Contractual Maturity	2 years	2 years

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (Fair Value, Measurements, Recurring, USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Fair Value, Assets and Liabilities Measured on Recurring Basis
Cash equivalents	$12,475	$9,802
Contingent consideration	24,843	24,335
Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis
Cash equivalents	375	1,302
Contingent consideration	0	0
Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis
Cash equivalents	12,100	8,500
Contingent consideration	0	0
Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Cash equivalents	0	0
Contingent consideration	24,843	24,335
Municipal Bonds
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	65,179	54,655
Municipal Bonds | Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Municipal Bonds | Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	65,179	54,655
Municipal Bonds | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Corporate Debt Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	74,501	92,629
Corporate Debt Securities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Corporate Debt Securities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	74,501	92,629
Corporate Debt Securities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Commercial Paper
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	37,429	44,671
Commercial Paper | Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Commercial Paper | Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	37,429	44,671
Commercial Paper | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Asset-backed Securities
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	22,085	21,283
Asset-backed Securities | Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Asset-backed Securities | Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	22,085	21,283
Asset-backed Securities | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Securities of U.S. government-sponsored agencies
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	10,593	8,548
Securities of U.S. government-sponsored agencies | Level 1
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	0	0
Securities of U.S. government-sponsored agencies | Level 2
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	10,593	8,548
Securities of U.S. government-sponsored agencies | Level 3
Fair Value, Assets and Liabilities Measured on Recurring Basis
Marketable Securities	$0	$0

INVENTORIES_Details

INVENTORIES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]
Raw Materials	$10,514	$8,847
Work in process	5,452	2,490
Finished goods	82,981	79,608
Total inventories	$98,947	$90,945

ACCRUED_EXPENSES_Details

ACCRUED EXPENSES (Details) (USD $)	Mar. 31, 2015	Dec. 31, 2014
In Thousands, unless otherwise specified
Payables and Accruals [Abstract]
Compensation and other employee-related costs	$14,756	$19,933
Legal and other settlements and expenses	27,042	27,686
Accrued non-income taxes	5,236	4,720
Other	10,783	9,160
Total accrued expenses	$57,817	$61,499

DEBT_Details

DEBT (Details) (Revolving Credit Facility, USD $)	3 Months Ended
In Millions, unless otherwise specified	Mar. 31, 2015
Debt Instrument
Credit facility, current borrowing capacity	$50
Credit facility, maximum borrowing capacity	75
Line of Credit, Termination Period Without Penalty	10 days
Fluctuating Rate Per Annum
Debt Instrument
Credit facility, variable rate	LIBOR
Credit facility, period of variable rate	1 month
Credit facility, basis spread on variable rate	0.75%
Fixed Rate
Debt Instrument
Credit facility, variable rate	LIBOR
Credit facility, basis spread on variable rate	0.75%
Fixed Rate | Minimum
Debt Instrument
Credit facility, period of variable rate	1 month
Fixed Rate | Maximum
Debt Instrument
Credit facility, period of variable rate	3 months
Letter of Credit
Debt Instrument
Credit facility, maximum borrowing capacity	$25

EQUITY_Textuals_Details

EQUITY (Textuals) (Details)	Mar. 31, 2015	Dec. 31, 2014
Class of Stock
Common stock, shares authorized	785,000,000
Class A Common
Class of Stock
Common stock, shares authorized	500,000,000	500,000,000
Class B Common
Class of Stock
Common stock, shares authorized	275,000,000	275,000,000
Class C Common
Class of Stock
Common stock, shares authorized	10,000,000

EQUITY_Schedule_of_Issued_and_

EQUITY (Schedule of Issued and Outstanding Shares) (Details)	Mar. 31, 2015	Dec. 31, 2014
Class of Stock
Common stock, shares issued	94,899,983	94,705,743
Common stock, shares outstanding	94,899,983	94,705,743
Class A Common
Class of Stock
Common stock, shares issued	71,022,427	70,828,187
Common stock, shares outstanding	71,022,427	70,828,187
Class B Common
Class of Stock
Common stock, shares issued	23,877,556	23,877,556
Common stock, shares outstanding	23,877,556	23,877,556

EQUITY_Stockholders_Equity_Rol

EQUITY Stockholders' Equity Rollforward (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Increase (Decrease) in Stockholders' Equity
Total equity, beginning of period	$585,454
Net income	24,648	21,139
Stock-based compensation	2,131
Exercise of stock options	1,425
Excess tax benefit of nonqualified stock options	684
Other comprehensive loss	-178	-2
Total equity, end of period	$614,164

EQUITY_Accumulated_Other_Compr1

EQUITY Accumulated Other Comprehensive Income (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013
Accumulated other comprehensive income/(loss), net of tax	($1,835)	($1,011)	($1,657)	($1,009)
Other comprehensive loss before reclassifications	-179	-8
Amounts reclassified from accumulated other comprehensive income, net of tax	1	6
Other comprehensive income/(loss), net of tax	-178	-2
Foreign Currency Translation Adjustment
Accumulated other comprehensive income/(loss), net of tax	-1,836	-1,044	-1,593	-1,041
Other comprehensive loss before reclassifications	-243	-3
Amounts reclassified from accumulated other comprehensive income, net of tax	0	0
Other comprehensive income/(loss), net of tax	-243	-3
Unrealized Gain/(Loss) on Marketable Securities, Net of Tax
Accumulated other comprehensive income/(loss), net of tax	1	33	-64	32
Other comprehensive loss before reclassifications	64	-5
Amounts reclassified from accumulated other comprehensive income, net of tax	1	6
Other comprehensive income/(loss), net of tax	$65	$1

STOCKBASED_COMPENSATION_Textua

STOCK-BASED COMPENSATION (Textuals) (Details) (USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award
Number of stock plans	3
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award
Maximum contractual term	10 years
Unrecognized compensation expense, unvested stock options	$24.20
Weighted average period of recognition, unvested stock options	3 years
Stock Options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award
Award vesting period	4 years
2012 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award
Base number of shares that may be issuable under stock plan	3,076,923
2012 Equity Incentive Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares available for grant	10,769,230
Annual percentage limit for incremental shares that may be issued	3.00%
2012 Equity Incentive Plan | Class A Common
Share-based Compensation Arrangement by Share-based Payment Award
Number of shares available for grant	4,958,899

STOCKBASED_COMPENSATION_Grant_

STOCK-BASED COMPENSATION (Grant Date Fair Values of Options Awarded to Employees) (Details) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant date per share fair value	$9.42	$10.34

STOCKBASED_COMPENSATION_Stock_

STOCK-BASED COMPENSATION (Stock Option Activity) (Details) (USD $)	3 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding
Number of shares outstanding beginning balance	4,854
Number of shares granted	1,159
Number of shares exercised	-194
Number of shares forfeited	-98
Number of shares outstanding ending balance	5,721
Number of shares exercisable	2,569
Number of shares expected to vest	3,152
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Weighted average exercise price per share outstanding beginning balance	$14.50
Weighted average exercise price per share granted	$23.98
Weighted average exercise price per share exercised	$7.34
Weighted average exercise price per share forfeited	$16.23
Weighted average exercise price per share outstanding ending balance	$16.63
Weighted average exercise price per share exercisable	$10.77
Weighted average exercise price per share expected to vest	$21.41
Weighted average remaining contractual life outstanding	7 years 7 months 6 days
Weighted average remaining contractual life exercisable	5 years 8 months 12 days
Weighted average remaining contractual life expected to vest	9 years 1 month 6 days
Aggregate intrinsic value outstanding	$49,236
Aggregate intrinsic value exercisable	37,164
Aggregate intrinsic value expected to vest	$12,073

STOCKBASED_COMPENSATION_Compen

STOCK-BASED COMPENSATION (Compensation Expense Related to Stock Options and Their Intrinsic Values) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Compensation expense related to stock options	$2,131	$1,927
Intrinsic value of stock options exercised	$3,260	$11,283

INCOME_TAXES_Details

INCOME TAXES (Details)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
Income Tax Disclosure [Abstract]
Effective income tax rate	35.40%	34.90%

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	3 Months Ended		12 Months Ended		3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013	Jul. 31, 2011	Oct. 31, 2010
						claim	claim
Loss Contingencies
Provision for litigation	$32,000	$2,535,000
Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation
Loss Contingencies
Loss Contingency, Pending Claims, Number						3
Damages awarded				16,000,000
Combined litigation loss				19,500,000
Provision for litigation - cost of goods sold				1,300,000
Provision for litigation			600,000	18,200,000
Synthes USA, LLC, Synthes USA Products, LLC, and Synthes USA Sales, LLC Litigation | Minimum
Loss Contingencies
Loss Contingency, Pending Claims, Number						1
NuVasive, Inc. Litigation
Loss Contingencies
Loss Contingency, Pending Claims, Number							3
NuVasive, Inc. Litigation | Minimum
Loss Contingencies
Loss Contingency, Pending Claims, Number							1
Bianco
Loss Contingencies
Combined litigation loss					4,300,000
Royalty Rate			5.00%
Altus Partners, LLC Litigation
Loss Contingencies
Provision for litigation		$2,000,000
N-Spine and Synthes Litigation | Minimum
Loss Contingencies
Loss Contingency, Pending Claims, Number				1	1

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Details) (USD $)	2 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Mar. 11, 2015	Mar. 31, 2014	Mar. 31, 2015	Dec. 31, 2014
Related Party Transactions [Abstract]
Accounts payable to related-party	$5,200		$0	$5,359
Purchases from related-party supplier	$5,304	$4,850

SEGMENT_AND_GEOGRAPHIC_INFORMA2

SEGMENT AND GEOGRAPHIC INFORMATION (Geographic Location) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
Revenues from External Customers
Total sales	$131,604	$114,210
United States
Revenues from External Customers
Total sales	119,983	101,705
International
Revenues from External Customers
Total sales	$11,621	$12,505

SEGMENT_AND_GEOGRAPHIC_INFORMA3

SEGMENT AND GEOGRAPHIC INFORMATION (Products) (Details) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2015	Mar. 31, 2014
	segments
	categories
Revenue from External Customer
Total sales	$131,604	$114,210
Textuals [Abstract]
Number of reportable segments	1
Number of product categories	2
Innovative Fusion
Revenue from External Customer
Total sales	70,370	66,770
Disruptive Technology
Revenue from External Customer
Total sales	$61,234	$47,440